Neoadjuvant chemoradiotherapy for resectable oesophageal cancer
At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-t...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Eyck, B.M. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Social capital and entrepreneurial activity: A pseudo-panel approach - Kim, Byung-Yeon ELSEVIER, 2014, London [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:36 ; year:2018 ; pages:37-44 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.bpg.2018.11.007 |
|---|
| Katalog-ID: |
ELV045183937 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV045183937 | ||
| 003 | DE-627 | ||
| 005 | 20230626010733.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190205s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bpg.2018.11.007 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000453.pica |
| 035 | |a (DE-627)ELV045183937 | ||
| 035 | |a (ELSEVIER)S1521-6918(18)30098-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 300 |q VZ |
| 082 | 0 | 4 | |a 330 |q VZ |
| 082 | 0 | 4 | |a 530 |a 620 |q VZ |
| 084 | |a 53.56 |2 bkl | ||
| 100 | 1 | |a Eyck, B.M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neoadjuvant chemoradiotherapy for resectable oesophageal cancer |
| 264 | 1 | |c 2018transfer abstract | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed. | ||
| 520 | |a At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed. | ||
| 650 | 7 | |a Oesophageal cancer |2 Elsevier | |
| 650 | 7 | |a Chemotherapy |2 Elsevier | |
| 650 | 7 | |a Chemoradiotherapy |2 Elsevier | |
| 650 | 7 | |a Response prediction |2 Elsevier | |
| 650 | 7 | |a Response evaluation |2 Elsevier | |
| 700 | 1 | |a van der Wilk, B.J. |4 oth | |
| 700 | 1 | |a Lagarde, S.M. |4 oth | |
| 700 | 1 | |a Wijnhoven, B.P.L. |4 oth | |
| 700 | 1 | |a Valkema, R. |4 oth | |
| 700 | 1 | |a Spaander, M.C.W. |4 oth | |
| 700 | 1 | |a Nuyttens, J.J.M.E. |4 oth | |
| 700 | 1 | |a van der Gaast, A. |4 oth | |
| 700 | 1 | |a van Lanschot, J.J.B. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Harcourt |a Kim, Byung-Yeon ELSEVIER |t Social capital and entrepreneurial activity: A pseudo-panel approach |d 2014 |g London [u.a.] |w (DE-627)ELV022528288 |
| 773 | 1 | 8 | |g volume:36 |g year:2018 |g pages:37-44 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.bpg.2018.11.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 53.56 |j Halbleitertechnologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 36 |j 2018 |h 37-44 |g 8 | ||
| author_variant |
b e be |
|---|---|
| matchkey_str |
eyckbmvanderwilkbjlagardesmwijnhovenbplv:2018----:eajvnceoaiteayorscalo |
| hierarchy_sort_str |
2018transfer abstract |
| bklnumber |
53.56 |
| publishDate |
2018 |
| allfields |
10.1016/j.bpg.2018.11.007 doi GBV00000000000453.pica (DE-627)ELV045183937 (ELSEVIER)S1521-6918(18)30098-2 DE-627 ger DE-627 rakwb eng 300 VZ 330 VZ 530 620 VZ 53.56 bkl Eyck, B.M. verfasserin aut Neoadjuvant chemoradiotherapy for resectable oesophageal cancer 2018transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed. At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed. Oesophageal cancer Elsevier Chemotherapy Elsevier Chemoradiotherapy Elsevier Response prediction Elsevier Response evaluation Elsevier van der Wilk, B.J. oth Lagarde, S.M. oth Wijnhoven, B.P.L. oth Valkema, R. oth Spaander, M.C.W. oth Nuyttens, J.J.M.E. oth van der Gaast, A. oth van Lanschot, J.J.B. oth Enthalten in Harcourt Kim, Byung-Yeon ELSEVIER Social capital and entrepreneurial activity: A pseudo-panel approach 2014 London [u.a.] (DE-627)ELV022528288 volume:36 year:2018 pages:37-44 extent:8 https://doi.org/10.1016/j.bpg.2018.11.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 53.56 Halbleitertechnologie VZ AR 36 2018 37-44 8 |
| spelling |
10.1016/j.bpg.2018.11.007 doi GBV00000000000453.pica (DE-627)ELV045183937 (ELSEVIER)S1521-6918(18)30098-2 DE-627 ger DE-627 rakwb eng 300 VZ 330 VZ 530 620 VZ 53.56 bkl Eyck, B.M. verfasserin aut Neoadjuvant chemoradiotherapy for resectable oesophageal cancer 2018transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed. At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed. Oesophageal cancer Elsevier Chemotherapy Elsevier Chemoradiotherapy Elsevier Response prediction Elsevier Response evaluation Elsevier van der Wilk, B.J. oth Lagarde, S.M. oth Wijnhoven, B.P.L. oth Valkema, R. oth Spaander, M.C.W. oth Nuyttens, J.J.M.E. oth van der Gaast, A. oth van Lanschot, J.J.B. oth Enthalten in Harcourt Kim, Byung-Yeon ELSEVIER Social capital and entrepreneurial activity: A pseudo-panel approach 2014 London [u.a.] (DE-627)ELV022528288 volume:36 year:2018 pages:37-44 extent:8 https://doi.org/10.1016/j.bpg.2018.11.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 53.56 Halbleitertechnologie VZ AR 36 2018 37-44 8 |
| allfields_unstemmed |
10.1016/j.bpg.2018.11.007 doi GBV00000000000453.pica (DE-627)ELV045183937 (ELSEVIER)S1521-6918(18)30098-2 DE-627 ger DE-627 rakwb eng 300 VZ 330 VZ 530 620 VZ 53.56 bkl Eyck, B.M. verfasserin aut Neoadjuvant chemoradiotherapy for resectable oesophageal cancer 2018transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed. At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed. Oesophageal cancer Elsevier Chemotherapy Elsevier Chemoradiotherapy Elsevier Response prediction Elsevier Response evaluation Elsevier van der Wilk, B.J. oth Lagarde, S.M. oth Wijnhoven, B.P.L. oth Valkema, R. oth Spaander, M.C.W. oth Nuyttens, J.J.M.E. oth van der Gaast, A. oth van Lanschot, J.J.B. oth Enthalten in Harcourt Kim, Byung-Yeon ELSEVIER Social capital and entrepreneurial activity: A pseudo-panel approach 2014 London [u.a.] (DE-627)ELV022528288 volume:36 year:2018 pages:37-44 extent:8 https://doi.org/10.1016/j.bpg.2018.11.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 53.56 Halbleitertechnologie VZ AR 36 2018 37-44 8 |
| allfieldsGer |
10.1016/j.bpg.2018.11.007 doi GBV00000000000453.pica (DE-627)ELV045183937 (ELSEVIER)S1521-6918(18)30098-2 DE-627 ger DE-627 rakwb eng 300 VZ 330 VZ 530 620 VZ 53.56 bkl Eyck, B.M. verfasserin aut Neoadjuvant chemoradiotherapy for resectable oesophageal cancer 2018transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed. At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed. Oesophageal cancer Elsevier Chemotherapy Elsevier Chemoradiotherapy Elsevier Response prediction Elsevier Response evaluation Elsevier van der Wilk, B.J. oth Lagarde, S.M. oth Wijnhoven, B.P.L. oth Valkema, R. oth Spaander, M.C.W. oth Nuyttens, J.J.M.E. oth van der Gaast, A. oth van Lanschot, J.J.B. oth Enthalten in Harcourt Kim, Byung-Yeon ELSEVIER Social capital and entrepreneurial activity: A pseudo-panel approach 2014 London [u.a.] (DE-627)ELV022528288 volume:36 year:2018 pages:37-44 extent:8 https://doi.org/10.1016/j.bpg.2018.11.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 53.56 Halbleitertechnologie VZ AR 36 2018 37-44 8 |
| allfieldsSound |
10.1016/j.bpg.2018.11.007 doi GBV00000000000453.pica (DE-627)ELV045183937 (ELSEVIER)S1521-6918(18)30098-2 DE-627 ger DE-627 rakwb eng 300 VZ 330 VZ 530 620 VZ 53.56 bkl Eyck, B.M. verfasserin aut Neoadjuvant chemoradiotherapy for resectable oesophageal cancer 2018transfer abstract 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed. At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed. Oesophageal cancer Elsevier Chemotherapy Elsevier Chemoradiotherapy Elsevier Response prediction Elsevier Response evaluation Elsevier van der Wilk, B.J. oth Lagarde, S.M. oth Wijnhoven, B.P.L. oth Valkema, R. oth Spaander, M.C.W. oth Nuyttens, J.J.M.E. oth van der Gaast, A. oth van Lanschot, J.J.B. oth Enthalten in Harcourt Kim, Byung-Yeon ELSEVIER Social capital and entrepreneurial activity: A pseudo-panel approach 2014 London [u.a.] (DE-627)ELV022528288 volume:36 year:2018 pages:37-44 extent:8 https://doi.org/10.1016/j.bpg.2018.11.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 53.56 Halbleitertechnologie VZ AR 36 2018 37-44 8 |
| language |
English |
| source |
Enthalten in Social capital and entrepreneurial activity: A pseudo-panel approach London [u.a.] volume:36 year:2018 pages:37-44 extent:8 |
| sourceStr |
Enthalten in Social capital and entrepreneurial activity: A pseudo-panel approach London [u.a.] volume:36 year:2018 pages:37-44 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Halbleitertechnologie |
| institution |
findex.gbv.de |
| topic_facet |
Oesophageal cancer Chemotherapy Chemoradiotherapy Response prediction Response evaluation |
| dewey-raw |
300 |
| isfreeaccess_bool |
false |
| container_title |
Social capital and entrepreneurial activity: A pseudo-panel approach |
| authorswithroles_txt_mv |
Eyck, B.M. @@aut@@ van der Wilk, B.J. @@oth@@ Lagarde, S.M. @@oth@@ Wijnhoven, B.P.L. @@oth@@ Valkema, R. @@oth@@ Spaander, M.C.W. @@oth@@ Nuyttens, J.J.M.E. @@oth@@ van der Gaast, A. @@oth@@ van Lanschot, J.J.B. @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV022528288 |
| dewey-sort |
3300 |
| id |
ELV045183937 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV045183937</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626010733.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">190205s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.bpg.2018.11.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000453.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV045183937</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1521-6918(18)30098-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">300</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">330</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">530</subfield><subfield code="a">620</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">53.56</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Eyck, B.M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Neoadjuvant chemoradiotherapy for resectable oesophageal cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oesophageal cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemoradiotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Response prediction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Response evaluation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van der Wilk, B.J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lagarde, S.M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wijnhoven, B.P.L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Valkema, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Spaander, M.C.W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nuyttens, J.J.M.E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van der Gaast, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van Lanschot, J.J.B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Harcourt</subfield><subfield code="a">Kim, Byung-Yeon ELSEVIER</subfield><subfield code="t">Social capital and entrepreneurial activity: A pseudo-panel approach</subfield><subfield code="d">2014</subfield><subfield code="g">London [u.a.]</subfield><subfield code="w">(DE-627)ELV022528288</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:36</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:37-44</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.bpg.2018.11.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">53.56</subfield><subfield code="j">Halbleitertechnologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">36</subfield><subfield code="j">2018</subfield><subfield code="h">37-44</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
| author |
Eyck, B.M. |
| spellingShingle |
Eyck, B.M. ddc 300 ddc 330 ddc 530 bkl 53.56 Elsevier Oesophageal cancer Elsevier Chemotherapy Elsevier Chemoradiotherapy Elsevier Response prediction Elsevier Response evaluation Neoadjuvant chemoradiotherapy for resectable oesophageal cancer |
| authorStr |
Eyck, B.M. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV022528288 |
| format |
electronic Article |
| dewey-ones |
300 - Social sciences 330 - Economics 530 - Physics 620 - Engineering & allied operations |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
300 VZ 330 VZ 530 620 VZ 53.56 bkl Neoadjuvant chemoradiotherapy for resectable oesophageal cancer Oesophageal cancer Elsevier Chemotherapy Elsevier Chemoradiotherapy Elsevier Response prediction Elsevier Response evaluation Elsevier |
| topic |
ddc 300 ddc 330 ddc 530 bkl 53.56 Elsevier Oesophageal cancer Elsevier Chemotherapy Elsevier Chemoradiotherapy Elsevier Response prediction Elsevier Response evaluation |
| topic_unstemmed |
ddc 300 ddc 330 ddc 530 bkl 53.56 Elsevier Oesophageal cancer Elsevier Chemotherapy Elsevier Chemoradiotherapy Elsevier Response prediction Elsevier Response evaluation |
| topic_browse |
ddc 300 ddc 330 ddc 530 bkl 53.56 Elsevier Oesophageal cancer Elsevier Chemotherapy Elsevier Chemoradiotherapy Elsevier Response prediction Elsevier Response evaluation |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
d w b v dwb dwbv s l sl b w bw r v rv m s ms j n jn d g a v dga dgav l j v lj ljv |
| hierarchy_parent_title |
Social capital and entrepreneurial activity: A pseudo-panel approach |
| hierarchy_parent_id |
ELV022528288 |
| dewey-tens |
300 - Social sciences, sociology & anthropology 330 - Economics 530 - Physics 620 - Engineering |
| hierarchy_top_title |
Social capital and entrepreneurial activity: A pseudo-panel approach |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV022528288 |
| title |
Neoadjuvant chemoradiotherapy for resectable oesophageal cancer |
| ctrlnum |
(DE-627)ELV045183937 (ELSEVIER)S1521-6918(18)30098-2 |
| title_full |
Neoadjuvant chemoradiotherapy for resectable oesophageal cancer |
| author_sort |
Eyck, B.M. |
| journal |
Social capital and entrepreneurial activity: A pseudo-panel approach |
| journalStr |
Social capital and entrepreneurial activity: A pseudo-panel approach |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
300 - Social sciences 500 - Science 600 - Technology |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
37 |
| author_browse |
Eyck, B.M. |
| container_volume |
36 |
| physical |
8 |
| class |
300 VZ 330 VZ 530 620 VZ 53.56 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Eyck, B.M. |
| doi_str_mv |
10.1016/j.bpg.2018.11.007 |
| dewey-full |
300 330 530 620 |
| title_sort |
neoadjuvant chemoradiotherapy for resectable oesophageal cancer |
| title_auth |
Neoadjuvant chemoradiotherapy for resectable oesophageal cancer |
| abstract |
At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed. |
| abstractGer |
At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed. |
| abstract_unstemmed |
At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
Neoadjuvant chemoradiotherapy for resectable oesophageal cancer |
| url |
https://doi.org/10.1016/j.bpg.2018.11.007 |
| remote_bool |
true |
| author2 |
van der Wilk, B.J. Lagarde, S.M. Wijnhoven, B.P.L. Valkema, R. Spaander, M.C.W. Nuyttens, J.J.M.E. van der Gaast, A. van Lanschot, J.J.B. |
| author2Str |
van der Wilk, B.J. Lagarde, S.M. Wijnhoven, B.P.L. Valkema, R. Spaander, M.C.W. Nuyttens, J.J.M.E. van der Gaast, A. van Lanschot, J.J.B. |
| ppnlink |
ELV022528288 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.bpg.2018.11.007 |
| up_date |
2024-07-06T16:50:08.201Z |
| _version_ |
1803849153330020352 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV045183937</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626010733.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">190205s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.bpg.2018.11.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000453.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV045183937</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1521-6918(18)30098-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">300</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">330</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">530</subfield><subfield code="a">620</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">53.56</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Eyck, B.M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Neoadjuvant chemoradiotherapy for resectable oesophageal cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">At present, treatment of potentially curable oesophageal cancer includes neoadjuvant chemoradiotherapy followed by oesophagectomy. Alternatively, neoadjuvant chemotherapy is used. To date, strong evidence on the superiority of one modality over the other has not been provided. Currently, up to one-third of patients show a pathologically complete response after neoadjuvant chemoradiotherapy. To optimise the efficacy of neoadjuvant treatment for individual patients, prediction of response to neoadjuvant treatment is highly desired. Therefore, several clinical diagnostic modalities have been investigated for early response evaluation, of which positron emission tomography (PET) has been studied most extensively. To identify patients who might benefit from postponing or even omitting surgery, recent advances have been made in evaluating response after completion of neoadjuvant chemoradiotherapy. This review provides an overview of current evidence and recent advances in neoadjuvant chemoradiotherapy for oesophageal cancer and discusses the use of neoadjuvant chemotherapy compared to chemoradiotherapy. Moreover, clinical response evaluation to neoadjuvant chemoradiotherapy is reviewed.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oesophageal cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemoradiotherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Response prediction</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Response evaluation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van der Wilk, B.J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lagarde, S.M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wijnhoven, B.P.L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Valkema, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Spaander, M.C.W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nuyttens, J.J.M.E.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van der Gaast, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van Lanschot, J.J.B.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Harcourt</subfield><subfield code="a">Kim, Byung-Yeon ELSEVIER</subfield><subfield code="t">Social capital and entrepreneurial activity: A pseudo-panel approach</subfield><subfield code="d">2014</subfield><subfield code="g">London [u.a.]</subfield><subfield code="w">(DE-627)ELV022528288</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:36</subfield><subfield code="g">year:2018</subfield><subfield code="g">pages:37-44</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.bpg.2018.11.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">53.56</subfield><subfield code="j">Halbleitertechnologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">36</subfield><subfield code="j">2018</subfield><subfield code="h">37-44</subfield><subfield code="g">8</subfield></datafield></record></collection>
|
| score |
7.400629 |